表紙
市場調査レポート

中国の臭化チオトロピウム市場の分析

Investigation Report on China Tiotropium Bromide Market, 2010-2019

発行 China Research and Intelligence 商品コード 297269
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
中国の臭化チオトロピウム市場の分析 Investigation Report on China Tiotropium Bromide Market, 2010-2019
出版日: 2015年06月04日 ページ情報: 英文 20 Pages
概要

世界各国と同様に中国でも大気汚染が悪化し、喘息や慢性閉塞性肺疾患(COPD)の患者数が増加し、それが関連治療薬の市場機会を拡大させています。Boehringer Ingelheim Groupが開発した、臭化チオトロピウムを用いた治療薬「Spiriva」は、2002年6月にオランダ・フィリピンで認可され、中国でも2006年に承認されました。同製品の売上高は全世界で2013年に50億米ドル近くに達しました。また、調査対象の病院向けの臭化チオトロピウムの売上高は、2006〜2014年の間、CAGR90%で推移し、1,400万元に達しました。今後も、産業発展と環境問題の解決の遅れから、喘息・COPDの患者数は増加し続け、臭化チオトロピウムの市場規模も拡大し続けるものと思われます。

当レポートでは、中国におけるチオトロピウム臭化物の市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 臭化チオトロピウムの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国の臭化チオトロピウム市場の概要

  • 特許および承認手続きの現状
  • 主要メーカー
  • 市場規模

第3章 臭化チオトロピウムの売上高の分析

  • 売上高(金額ベース)
  • 売上高(数量ベース)

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 臭化チオトロピウムの病院向け基準価格(企業別)

  • Boehringer Ingelheim
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第7章 主要メーカーの分析

  • Boehringer Ingelheim
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第8章 中国の臭化チオトロピウム市場の将来展望

  • 市場規模の予測
  • 競合状況の予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506195

In recent years, various allergic diseases demonstrate an increasing trend under the influence of global environmental changes, leading to the occurrence of seasonal cough and asthma in winter and spring. Affected by tobacco, dust and pollutants, the incidence of chronic obstructive pulmonary disease (COPD) is still on the rise. COPD is a chronic pulmonary disease characterized by incompletely reversible airflow obstruction. The major clinical manifestations are recurrent cough, expectoration, dyspnea. COPD often demonstrate a progressive characteristic, including large parts of chronic bronchitis and emphysema.

According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003-2033.

For many years, the COPD market and anti-asthmatic agents market have been dominated by four big companies - GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.

Tiotropium bromide, a long-acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD's clinical course so as to help improve the state of patient's life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.

According to CRI's survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006-2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.

It is expected that in the next few years, tiotropium bromide market in China will keep expanding fast.

Readers can get at least the following information through this report:

  • market share of manufacturers of tiotropium bromide in Chinese hospitals
  • price of tiotropium bromide in Chinese hospitals
  • major manufacturers of tiotropium bromide in Chinese market
  • share of different dosage forms of tiotropium bromide in Chinese hospitals
  • market outlook of tiotropium bromide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of COPD drugs
  • investors interested in China COPD drug market

Table of Contents

1. Related Concepts of Tiotropium Bromide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Tiotropium Bromide in China

  • 2.1. Patent and Approval Status of Tiotropium Bromide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Tiotropium Bromide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Tiotropium Bromide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Tiotropium Bromide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Tiotropium Bromide in Chinese Hospitals in 2014

  • 6.1. Boehringer Ingelheim (Germany) (Trade Name: Spiriva)
  • 6.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Sule)
  • 6.3. Zhejiang Xianju Pharmaceutical Co., Ltd (Trade Name: Biduoyi)

7. Major Manufacturers of Tiotropium Bromide in Chinese Market, 2010-2014

  • 7.1. Boehringer Ingelheim (Germany)
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.3. Zhejiang Xianju Pharmaceutical Co., Ltd

8. Market Outlook of Tiotropium Bromide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Tiotropium Bromide in China
  • Chart Approval Information of Tiotropium Bromide in China
  • Chart Sales Status of Tiotropium Bromide in Chinese Market, 2010-2014
  • Chart Sales Value of Tiotropium Bromide in China, 2010-2014
  • Chart Sales Value of Tiotropium Bromide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Tiotropium Bromide in China, 2010-2014
  • Chart Market Share of Top3 Manufacturers of Tiotropium Bromide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Xianju Pharmaceutical in China, 2010-2014
  • Chart Price of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Tiotropium Bromide Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Tiotropium Bromide Made by Zhejiang Xianju Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top